3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
17
Carcinoma, Renal Cell
7
Multiple Myeloma
4
Recurrence
3
Leukemia
3
Carcinoma, Hepatocellular
3
Triple Negative Breast Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Lymphoma
2
Breast Neoplasms
2
Uveal Melanoma
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Small Cell Lung Carcinoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Oligodendroglioma
1
Neoplasms, Plasma Cell
1
Mycosis Fungoides
1
Lymphoma, T-Cell
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Liver Neoplasms
1
Liver Cirrhosis
1
Leukemia-Lymphoma, Adult T-Cell
1
Kidney Neoplasms
1
Hepatitis C, Chronic
1
Hepatitis C
1
Interventions
Amifostine
12
Cisplatin
10
Radiotherapy
8
Etoposide
8
Cyclophosphamide
5
Paclitaxel
4
Filgrastim
4
Gemcitabine
3
Cytarabine
3
Carboplatin
3
denileukin diftitox
2
apatinib
2
Vincristine
2
Pyridoxine
2
Irinotecan
2
Ifosfamide
2
Fibroblast Growth Factor 7
2
Epoetin Alfa
2
Doxorubicin
2
Dexamethasone
2
Chemotherapy, Adjuvant
2
Bleomycin
2
uridine triacetate
1
sargramostim
1
peginterferon alfa-2b
1
pegfilgrastim
1
pegaspargase
1
eribulin
1
camrelizumab
1
Vitamin E
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Drug-Related Side Effects and Adverse Reactions
×
Introns
×
Clear all
NCT00221702
2010-10-13
EADO
University Hospital, Bordeaux
Phase 3
Completed
898 enrolled